Biomanufacturing Expansion: Argentine biosimilars maker Biosidus finished a $12.9M biomanufacturing upgrade, tripling cell culture capacity to support its Fabry disease agalsidase beta biosimilar and future international partnerships. Medicare Advantage Scrutiny: A new study finds Medicare Advantage enrollees with a new complex diagnosis are more likely to leave for traditional Medicare, raising concerns about access and plan switching barriers. COVID-19 Vaccines: FDA cleared updated COVID-19 shots, with guidance focused on older adults and people with higher-risk conditions, while healthy younger adults are urged to discuss risk with clinicians. Cardiometabolic Breakthrough: FDA approved Mounjaro (tirzepatide) to reduce major cardiovascular events in adults with type 2 diabetes, showing an 8% lower rate of cardiovascular death, heart attack, or stroke vs Trulicity. HIV Treatment Update: FDA approved Gilead’s Bixlenvo, a once-daily single-tablet regimen for virologically suppressed HIV patients. Healthcare Policy & Access: CMS’s DMEPOS supplier enrollment moratorium ended Aug. 27, and the AHA urged CMS to avoid payment and enrollment changes that could increase reporting burdens and threaten beneficiary access. Public Health Gap: JAMA Network Open reports a sharp rise in never-screened cervical cancer rates among young U.S. women, with later-stage incidence increasing after 2017. AI in Care: Cleveland Clinic’s AI Summit highlighted how AI is entering clinical workflows, while local hospitals test tools to improve care and cut costs. R&D Funding Push: Philippines’ DOST proposed a 2027 budget emphasizing R&D and STEM, including major support for grants and research institutes.